Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease

NCT06088979 is registered in ClinicalTrials.gov with Tourmaline Bio, Inc., a Novartis Company as lead sponsor.

NCT NCT06088979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06088979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease
Lead sponsor
Tourmaline Bio, Inc., a Novartis Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 19, 2024
Completion date
September 30, 2027
Enrollment
79 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease